Effect of Surgical Treatment of Morbid Obesity on Fatty Liver
Margret Lino Wuor Abyei;
Abstract
Obesity is an international epidemic that is associated with multiple health problems and has been increasing worldwide over the last few decades.
The prevalence of obesity ranges from 9% to 26%, and the prevalence of morbid obesity, which is a known risk factor for metabolic syndrome, diabetes mellitus and cardiovascular diseases, ranges from 1.4% to 7%.
The incidence of obesity continues its steady rise towards most lethal disease status. The incidence in Egypt in 2006 was about 30.3% in both sexes.
Overweight and obesity are associated with increased rate of type II diabetes mellitus, hypertension, cardiovascular diseases, dyslipidemia, arthritis, non-alcoholic steatohepatitis, gallbladder disease, sleep apnea syndrome and several cancers. Mortality increases with increasing body mass index. Mortality rate is twelve times than that in young normal weight men.
Obesity also contributes to several sleep-related breathing disorder (SBD), including obstructive sleep apnoea (OSA) and obesity hypoventilation syndrome (OHS).
Non alcoholic fatty liver disease is a spectrum that is initiated with steatosis; it can progress to non alcoholicsteatohepatitis (NASH) and later fibrosis, cirrhosis, and potentially end-stage liver failure and/or hepatocellular carcinoma, in the absence of chronic alcohol use or other liver disease Surgical weight loss operations, probably by reversing metabolic syndrome, have been shown to result in improvement in liver histology.
Metabolic syndrome is present in 60% of females and 30% of males with non alcoholic fatty liver disease and this association rises with increasing BMI, from 18% in lean individuals to 67% of obese patients.
Intuitively, it follows that weight loss should be a therapeutic factor for non alcoholic fatty liver disease and, indeed, has been demonstrated previously by several investigators.
However, it is often difficult to achieve sustained weight loss in morbidly obese patients with diet and exercise alone. Bariatric surgery, especially Roux-en-Y gastric bypass, has proved to be effective for achieving sustained weight loss in these patients and is thought to be an attractive option in reversing many metabolic risk factors associated with NAFLD. Studies have shown that majority of patients achieve improvement or complete resolution of NAFLD, including steatosis, NASH, and fibrosis, after weight loss induced by
The prevalence of obesity ranges from 9% to 26%, and the prevalence of morbid obesity, which is a known risk factor for metabolic syndrome, diabetes mellitus and cardiovascular diseases, ranges from 1.4% to 7%.
The incidence of obesity continues its steady rise towards most lethal disease status. The incidence in Egypt in 2006 was about 30.3% in both sexes.
Overweight and obesity are associated with increased rate of type II diabetes mellitus, hypertension, cardiovascular diseases, dyslipidemia, arthritis, non-alcoholic steatohepatitis, gallbladder disease, sleep apnea syndrome and several cancers. Mortality increases with increasing body mass index. Mortality rate is twelve times than that in young normal weight men.
Obesity also contributes to several sleep-related breathing disorder (SBD), including obstructive sleep apnoea (OSA) and obesity hypoventilation syndrome (OHS).
Non alcoholic fatty liver disease is a spectrum that is initiated with steatosis; it can progress to non alcoholicsteatohepatitis (NASH) and later fibrosis, cirrhosis, and potentially end-stage liver failure and/or hepatocellular carcinoma, in the absence of chronic alcohol use or other liver disease Surgical weight loss operations, probably by reversing metabolic syndrome, have been shown to result in improvement in liver histology.
Metabolic syndrome is present in 60% of females and 30% of males with non alcoholic fatty liver disease and this association rises with increasing BMI, from 18% in lean individuals to 67% of obese patients.
Intuitively, it follows that weight loss should be a therapeutic factor for non alcoholic fatty liver disease and, indeed, has been demonstrated previously by several investigators.
However, it is often difficult to achieve sustained weight loss in morbidly obese patients with diet and exercise alone. Bariatric surgery, especially Roux-en-Y gastric bypass, has proved to be effective for achieving sustained weight loss in these patients and is thought to be an attractive option in reversing many metabolic risk factors associated with NAFLD. Studies have shown that majority of patients achieve improvement or complete resolution of NAFLD, including steatosis, NASH, and fibrosis, after weight loss induced by
Other data
| Title | Effect of Surgical Treatment of Morbid Obesity on Fatty Liver | Other Titles | تأثير العلاج الجراحي للسمنة المرضية على الكبد الدهني | Authors | Margret Lino Wuor Abyei | Issue Date | 2014 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.